Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M-Unity: Beta-glucan for Influenza Vaccine Response
NCT05074303Phase 2Completed
- Sponsor
- University of Florida
- Start
- Jul 2022
- Primary completion
- Mar 2024
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial (2 arms), sponsored by University of Florida. Primary endpoint: Antibody Titer at Day 42. Started Jul 2022; status: completed.
Beyond the preview
Go deeper on NCT05074303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05074303.